6 edition of Protein-protein interactions as new drug targets found in the catalog.
Includes bibliographical references and index.
|Statement||Enno Klussmann, John Scott, editors ; contributors, E.M. Aandahl ... [et al.].|
|Series||Handbook of experimental pharmacology -- v. 186|
|Contributions||Klussmann, Enno., Scott, John, Ph. D., Aandahl, E. M.|
|LC Classifications||RM301.63 .P76 2008|
|The Physical Object|
|Pagination||xv, 512 p. :|
|Number of Pages||512|
|ISBN 10||3540728422, 3540728430|
|ISBN 10||9783540728429, 9783540728436|
|LC Control Number||2008920053|
Protein–Protein Interactions Ashley E. Modell,1,z Sarah L. Blosser,1,z and Paramjit S. Arora1,* Over the past decade, protein–protein interactions (PPIs) have gone from being neglected as ‘undruggable’ to being considered attractive targets for the devel-opment of therapeutics. Recent advances in computational analysis, fragment-based lized. Similar Items. Protein-protein interactions as new drug targets Published: () ; Small-molecule inhibitors of protein-protein interactions Published: () ; Protein-protein interaction Published: () ; Proteomics and protein-protein interactions biology, chemistry, bioinformatics, and drug design / Published: ().
Protein-protein interactions and allosterically regulated enzymes have been challenging but important targets for probe- and drug discovery, especially in the inflammation field. We and others have found that fragment-based lead discovery can provide chemical starting points and furthermore serve as insightful probes of protein conformation. Protein-protein interactions and biosynthetic building blocks may be targeted as well. Other drug targets include lipids and carbohydrates. However, the number of drugs that act on these targets is relatively small compared to drugs that target proteins and nucleic acids. Further Reading. Drugs, their targets and the nature and number of drug.
Realizing the promise of molecularly targeted inhibitors for cancer therapy will require a new level of knowledge about how a drug target is wired into the control circuitry of a complex cellular. Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation.
McCune State Bank.
Proceedings of IUTAM Symposium on Impact Dynamics
The professional counselor
Late 1980s phenomena of out-of-town shopping centres.
Two suitcases and a dog
Measurement of scientific and technological activities
Catalogue of the Sigma Phi
Appraisers warehouse in the City of New York.
Productivity, Innovation, Management and Development
Oxygen Therapy - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
Daughters of Ishmael.
Composition leaflets on Philippine activities
The Vegetarian Guide to Diet and Salad
Drugs targeting such interactions are likely to act with fewer side effects than conventional medication influencing whole cell functions. This book discusses therapeutically relevant protein-protein interactions with a major focus on scaffolding proteins tethering signal transduction processes to defined cellular compartments by direct protein-protein : Hardcover.
Disease-relevant intracellular protein-protein interactions occurring at defined cellular sites possess great potential as drug targets. They permit highly specific pharmacological interference with defined cellular functions. Protein Interactions as Targets in Drug Discovery, Volumeis dedicated to the design of therapeutics, both experimental and computational, that target protein interactions.
Chapters in this new release include Trends in structure based drug design with protein targets, From fragment- to peptide-protein interaction: addressing the structural basis of binding using Supervised Molecular Dynamics (SuMD), Protein-protein and protein-ligand interactions.
Drugs targeting such interactions are likely to act with fewer side effects than conventional medication influencing whole cell functions. This book discusses therapeutically relevant protein-protein interactions with a major focus on scaffolding proteins tethering signal transduction processes to defined cellular compartments by direct protein-protein interactions.
Protein-Protein Interactions as Drug Targets. Shaomeng Wang, Yujun Zhao, Denzil Bernard, Angelo Aguilar, Sanjeev Kumar Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics.
Kurt Deshayes, Jeremy Murray, Domagoj Vucic The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer. Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation.
This book comprehensively reviews the state-of-the-art strategies developed for protein-protein interaction (PPI) inhibitors, and highlights the success stories in new drug discovery and development. Consisting of two parts with twelve chapters, it demonstrates the design strategies and case studies of small molecule PPI inhibitors.
Protein–protein interactions as drug targets. Modulation of protein–protein interactions (PPIs) is becoming increasingly important in drug discovery and chemical biology. While a few years ago this ‘target class’ was deemed to be largely undruggable an impressing number of publications and success stories now show that targeting PPIs with small, drug-like molecules indeed.
Protein-Protein Interactions as Potential Targets of Drug Designing Zeeshan Zahoor Banday1; Ghulam Md Ashraf * 1School of Life Sciences, Jawaharlal Nehru University, New Delhi, India *Correspondence to: Ghulam Md Ashraf, King Fahd Medical Research Center, King Abdulaziz University, P.
BoxJeddahSaudi Arabia. Tel: + ; E-mail: @. Protein–protein interactions (PPIs) recently have been recognized as a major class of drug targets. Many of the successful “classical” biotechnology protein drugs are agonists or antagonists of PPIs and there are established pathways for their : Alexander Dömling.
Sickness-associated intracellular protein-protein interactions occurring at outlined cellular websites possess good potential as drug targets. They permit. Handb Exp Pharmacol. ;():v-vi. Protein-protein interactions as new drug targets. Preface. Klussmann E, Rosenthal W. PMID: Cited by: 2.
This book comprehensively reviews the state-of-the-art strategies developed for protein-protein interaction (PPI) inhibitors, and highlights the success stories in new drug discovery and development. Consisting of two parts with twelve chapters, it demonstrates the design strategies and case studies of small molecule PPI : Chunquan Sheng, Gunda I.
Georg. interaction modulators. Modern drug discovery is molecular target driven with the aim of identifying new thera-peutic agents that can selectively target disease-specific molecular mechanisms or pathways.
In this context, protein–protein (PP) interactions (PPIs) are an attractive emerging class of molecu-lar targets. Critical cellular. Protein–protein interactions (PPIs) are increasingly being targeted by drug discovery groups, and there exists great scope for therapeutic modulation of this target class in by: Modulation of protein-protein interactions (PPIs) is becoming increasingly important in drug discovery and chemical biology.
While a few years ago this 'target class' was deemed to be largely. Introduction. The classification of protein–protein interactions (PPI) as druggable targets is relatively new. If one considers druggability as the ability to modulate the therapeutic target with a small orally available molecule , the first review that included small molecules as antagonists of PPI dates from .However, progress was initially slowed by a focus on discovery tools Cited by: ISBN: OCLC Number: Description: xv, pages: illustrations: Contents: PART I: ORGANIZATION OF SCAFFOLDS --A-Kinase Anchoring Proteins as the Basis for cAMP Signaling / K.L.
Dodge-Kafka, A. Bauman, and M.S. Kapiloff --Arrestins as Multi-Functional Signaling Adaptors / V.V. Gurevich, E.V. Gurevich, and W.M. This book discusses therapeutically relevant protein-protein interactions with a major focus on scaffolding proteins tethering signal transduction processes to defined cellular compartments by direct protein-protein interactions.
Introduction: targeting protein–protein interactions. Pharmaceutical R&D undergoes a decline of productivity as the number of new drugs approved by the FDA regularly decreases.
Besides market forces and difficulties such as demand and competition. Protein–protein interactions (PPIs) control a large number of biological processes. An attempt to design novel drug molecules has led to an increasing interest in the protein surfaces.
However, a new type of intracellular drug target—Protein-Protein Interactions (PPIs)—are now expanding the space in which to search for new types of medicines.
PPIs are protein complexes inside the cell that play regulatory or structural roles.Such protein-protein interaction (PPI) complexes can be considered a type of drug target. PPI targets are different from traditional drug targets that comprise of a single protein, more specifically an enzyme, whose function is targeted for reduction by a chemical inhibitor.